Joseph Tuscano
Clinical trials sponsored by Joseph Tuscano, explained in plain language.
-
New hope for hard-to-treat lymphoma: targeted therapy plus chemo shows promise
Disease control Recruiting nowThis study tests a two-step treatment for people with a fast-growing type of lymphoma that hasn't been treated yet. First, a targeted drug (loncastuximab tesirine) plus rituximab is given, followed by a standard chemotherapy cocktail (DA-EPOCH-R). The goal is to see if this appro…
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 26, 2026 10:10 UTC
-
Could a Two-Punch approach beat tough lymphoma?
Disease control Recruiting nowThis study tests whether adding the drug odronextamab before and after standard CAR T-cell therapy helps people with diffuse large B-cell lymphoma that has returned or not responded to prior treatments. About 34 adults will receive odronextamab to help their immune T-cells find a…
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 26, 2026 10:09 UTC
-
New combo therapy aims to boost lymphoma remission after transplant
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy and a stem cell transplant can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatment. About 25 adults will receive epcoritamab plus chemotherapy be…
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 26, 2026 10:05 UTC